Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II

Trial Profile

Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Degarelix; Goserelin; Leuprorelin; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2018.
    • 28 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top